If you are researching weight loss medication in the UK, you have probably come across two of the most widely discussed options: Mounjaro (tirzepatide) and Wegovy (semaglutide).
Both are prescription medicines used for weight management and both are given as once-weekly injections. They can help reduce appetite, increase feelings of fullness and support weight loss when used alongside a reduced-calorie diet and increased physical activity.
However, Mounjaro and Wegovy are not the same medicine. They work through different hormone pathways, have different active ingredients and may not be suitable for everyone.
So, Mounjaro vs Wegovy — which is better for weight loss?
The answer depends on your health, medical history, treatment goals, response to medication and advice from a qualified healthcare professional.
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It works on two hormone pathways involved in appetite regulation, food intake and blood glucose control.
For weight management, Mounjaro is used alongside a reduced-calorie diet and increased physical activity. UK product information indicates it can be used for adults with a BMI of 30 kg/m² or above, or adults with a BMI of at least 27 kg/m² but below 30 kg/m² who have at least one weight-related health condition.
Mounjaro is administered once a week.
What Is Wegovy?
Wegovy contains semaglutide, a GLP-1 receptor agonist.
Semaglutide mimics the action of GLP-1, a hormone involved in appetite and satiety. By activating GLP-1 receptors, Wegovy can help reduce hunger and increase feelings of fullness.
Wegovy is also used alongside a reduced-calorie diet and increased physical activity for weight management. UK product information lists it for adults with obesity or adults who are overweight and have at least one weight-related health condition.
Wegovy is also administered once weekly for its injectable weight-management formulation.
Mounjaro vs Wegovy: The Main Difference
The biggest difference is how the medicines work.
| Mounjaro | Wegovy | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Main action | GIP + GLP-1 | GLP-1 |
| Type | Dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonist |
| Weight management | Yes | Yes |
| Injection | Once weekly | Once weekly |
| Used with diet and exercise | Yes | Yes |
Mounjaro activates both GIP and GLP-1 receptors, while Wegovy primarily activates the GLP-1 receptor.
Both can influence appetite, hunger and feelings of fullness, but they achieve this through different mechanisms.
Which Works Better for Weight Loss: Mounjaro or Wegovy?
One of the most important recent developments is that there is now direct clinical trial evidence comparing tirzepatide with semaglutide for obesity.
In the SURMOUNT-5 trial, adults with obesity or overweight with at least one weight-related health condition were randomly assigned to tirzepatide or semaglutide alongside lifestyle measures.
After 72 weeks, the reported average reduction in body weight was:
- Tirzepatide: 21.6%
- Semaglutide: 15.4%
Tirzepatide therefore produced a greater average reduction in body weight in this particular trial.
However, clinical trial results represent averages across groups. They cannot predict exactly how much weight an individual will lose.
Your results may depend on factors such as:
- Starting weight
- BMI
- Dose
- Diet
- Physical activity
- Medical conditions
- Other medicines
- Treatment adherence
- Individual response
Therefore, it would be inaccurate to say that Mounjaro is automatically the best choice for everyone.
How Does Mounjaro Work?
Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors.
These hormone pathways are involved in appetite and energy regulation. Tirzepatide can help:
- Reduce hunger
- Increase feelings of fullness
- Reduce food cravings
- Reduce food intake
- Delay gastric emptying, particularly after meals
- Improve blood glucose regulation
These effects can make it easier for some people to consume fewer calories while following a reduced-calorie diet.
How Does Wegovy Work?
Wegovy contains semaglutide, which acts on the GLP-1 receptor.
It can help regulate appetite and increase feelings of fullness, which may reduce food intake.
Like Mounjaro, Wegovy is not intended to work as a standalone replacement for healthy eating and physical activity. It is used as part of a broader weight management programme.
Mounjaro vs Wegovy Dosage
Both treatments use a gradual dose-escalation approach rather than immediately starting at the highest dose.
Mounjaro
Mounjaro generally starts at 2.5 mg once weekly. After four weeks, the dose is normally increased to 5 mg once weekly. Further increases can be made in 2.5 mg increments after at least four weeks on the current dose, depending on clinical response and tolerability.
The maximum recommended adult dose is 15 mg once weekly.
Wegovy
Injectable Wegovy also starts at a low dose and is gradually increased.
The standard escalation schedule for the injectable formulation begins at 0.25 mg once weekly, followed by increases through 0.5 mg, 1 mg and 1.7 mg before reaching a maintenance dose.
The appropriate dose depends on the individual patient and tolerability.
Never change your dose without advice from your prescriber.
Mounjaro vs Wegovy Side Effects
Both medicines can cause gastrointestinal side effects because they affect the digestive system and appetite.
Common side effects can include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal discomfort
- Indigestion
- Bloating
- Reflux or heartburn
These effects can be particularly noticeable when the dose is being increased.
With either medicine, persistent or severe symptoms should be discussed with a healthcare professional.
Mounjaro Side Effects
Common gastrointestinal effects reported with tirzepatide include nausea, diarrhoea, constipation and vomiting.
Wegovy Side Effects
Wegovy can also cause gastrointestinal effects including nausea, vomiting, diarrhoea, constipation and abdominal pain.
The fact that both medicines can cause similar side effects does not mean they are equally suitable for every patient.
Who May Be Eligible for Mounjaro?
UK product information states that Mounjaro can be used for weight management in adults with:
- A BMI of 30 kg/m² or above, or
- A BMI of 27 kg/m² to below 30 kg/m² with at least one weight-related health condition.
Examples of weight-related conditions include hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes and type 2 diabetes.
However, NHS eligibility is more specific than the medicine’s licensed indication. NHS access is being introduced in phases and depends on clinical criteria and the relevant NHS pathway.
Private treatment also requires an appropriate clinical assessment.
Who May Be Eligible for Wegovy?
Wegovy’s UK product information states that it can be used for weight management in adults with:
- A BMI of 30 kg/m² or above, or
- A BMI of 27 kg/m² to below 30 kg/m² with at least one weight-related health condition.
NHS access is subject to additional eligibility requirements and specialist weight management pathways.
For example, NHS England currently states that Wegovy may be considered through specialist services for people meeting specific BMI and health criteria.
Mounjaro vs Wegovy: Which Has Better Results?
Based on current head-to-head trial evidence, tirzepatide produced greater average weight loss than semaglutide in the SURMOUNT-5 study.
At 72 weeks:
Mounjaro/tirzepatide: average weight reduction of 21.6%
Wegovy/semaglutide: average weight reduction of 15.4%
This is useful evidence when comparing the medicines, but it should not be interpreted as a promise of individual results.
A person may respond very well to Wegovy, while another may respond better to Mounjaro. Treatment decisions should therefore consider the whole clinical picture rather than weight loss percentages alone.
Mounjaro vs Wegovy for Appetite Control
Both medicines can help reduce appetite.
Mounjaro acts on both GIP and GLP-1 pathways, while Wegovy acts primarily through GLP-1.
People taking either treatment may find that:
- They feel full sooner
- Their portions become smaller
- They feel less hungry between meals
- Food cravings may decrease
- They find it easier to maintain a calorie deficit
The extent of appetite reduction varies from person to person.
Which Is Better for Type 2 Diabetes?
Tirzepatide and semaglutide can both have effects on blood glucose, but they are different medicines with different licensed indications and treatment pathways.
Mounjaro is licensed in the UK for the treatment of type 2 diabetes as well as weight management.
Wegovy is a semaglutide formulation specifically indicated for weight management, while other semaglutide products are used for type 2 diabetes.
If you have diabetes and are considering weight loss medication, your existing diabetes medicines and blood glucose control need to be considered by your healthcare professional.
Mounjaro vs Wegovy: Which Is More Suitable for You?
There is no universal answer.
Mounjaro may be considered where a clinician believes its dual GIP/GLP-1 action and clinical profile are appropriate.
Wegovy may be suitable for another patient based on their medical history, treatment response, tolerability and individual circumstances.
Your healthcare professional may consider:
- BMI
- Weight-related health conditions
- Current medicines
- Medical history
- Previous weight loss attempts
- Treatment goals
- Potential side effects
- Contraindications
- Pregnancy or breastfeeding
- Your response to treatment
The most effective medicine on average is not necessarily the safest or most appropriate medicine for every individual.
Can You Take Mounjaro and Wegovy Together?
No. You should not combine Mounjaro and Wegovy unless specifically instructed by an appropriately qualified healthcare professional, and these medicines are generally alternatives rather than treatments to use together.
Both affect appetite-related hormone pathways, and combining weight-management medicines without appropriate clinical supervision could increase the risk of adverse effects.
If you are considering switching from one treatment to another, speak with your prescriber first.
Mounjaro vs Wegovy: NHS vs Private Treatment
There is an important difference between being eligible for a medicine under its UK licence and meeting the criteria for NHS-funded treatment.
NHS England currently has specific pathways for weight management medicines.
For example, NHS access to Mounjaro is being introduced gradually, with initial primary-care access focused on people with the highest clinical need.
Wegovy access through the NHS also follows specific specialist weight management criteria.
Private prescribing is separate. A private healthcare provider should still carry out an appropriate clinical assessment before prescribing either medicine.
What About Diet and Exercise?
Both Mounjaro and Wegovy are intended to be used alongside lifestyle changes.
This means treatment should generally be combined with:
- A balanced, reduced-calorie diet
- Adequate protein and fibre
- Appropriate portion sizes
- Regular physical activity
- Healthy sleep habits
- Ongoing weight management support
NHS England specifically states that people using weight management injections should follow a balanced reduced-calorie diet and participate in regular physical activity.
Medication can support weight loss, but it should not replace healthy lifestyle habits.
What Happens If You Stop Mounjaro or Wegovy?
Weight management treatment may need to be considered over the longer term.
Stopping treatment can result in increased appetite and weight regain in some people. The Mounjaro product information includes evidence that continued tirzepatide treatment helped maintain weight loss compared with switching to placebo after initial weight reduction.
If you are thinking about stopping treatment, speak to your prescriber. They can discuss your options and help you develop a suitable long-term weight management plan.
Frequently Asked Questions
Is Mounjaro better than Wegovy for weight loss?
Clinical trial evidence from SURMOUNT-5 found greater average weight loss with tirzepatide than semaglutide after 72 weeks. However, this does not mean Mounjaro is automatically better for every individual.
What is the difference between Mounjaro and Wegovy?
Mounjaro contains tirzepatide and activates both GIP and GLP-1 receptors. Wegovy contains semaglutide and primarily activates GLP-1 receptors.
Which has fewer side effects, Mounjaro or Wegovy?
Both can cause gastrointestinal side effects such as nausea, vomiting, diarrhoea and constipation. Individual tolerance varies, so one cannot be considered universally better for side effects.
Can I switch from Wegovy to Mounjaro?
A switch may be possible for some patients, but it should only be done under the guidance of a qualified healthcare professional. Your prescriber can advise on the appropriate treatment and dosing approach.
Is Mounjaro available privately in the UK?
Yes. Mounjaro can be prescribed privately following an appropriate clinical assessment if a qualified prescriber determines that it is suitable.
Is Wegovy available privately in the UK?
Yes. Wegovy can be prescribed privately for eligible patients following an appropriate clinical assessment.
Do Mounjaro and Wegovy require diet and exercise?
Yes. Both medicines are intended to be used alongside a reduced-calorie diet and increased physical activity.
Can I take Mounjaro or Wegovy if I am pregnant?
Weight management with these medicines is not recommended during pregnancy. If you are pregnant, planning a pregnancy or breastfeeding, speak with your healthcare professional before using weight loss medication.
Final Verdict: Mounjaro or Wegovy?
So, Mounjaro vs Wegovy — which weight loss treatment is right for you?
Both are clinically established prescription treatments for weight management, but they work differently.
Mounjaro (tirzepatide) activates both GIP and GLP-1 receptors and has produced greater average weight loss than semaglutide in a recent head-to-head clinical trial.
Wegovy (semaglutide) is a GLP-1 receptor agonist with established evidence for weight management and remains an important treatment option for eligible patients.
The right choice should be based on your health, BMI, medical history, existing medicines, treatment goals, potential risks, tolerability and clinical assessment rather than simply choosing the medicine associated with the highest average weight loss.
If you are considering Mounjaro or Wegovy in the UK, a confidential online consultation with a qualified healthcare professional can help determine whether prescription weight management treatment may be appropriate for you.
Private Pharmacy Care provides online weight management consultations for eligible patients seeking professional guidance about prescription weight loss treatment.